The increasing need for radioimmunoassay is mainly driven
by the rising occurrence of cancer, infectious diseases, and
various other health conditions, along with a growing number of
epidemics and pandemics and increasing health awareness. Moreover,
the radioimmunoassay market is expected to expand due to numerous
ongoing research endeavors in this domain, partnerships between
healthcare providers, researchers, and industry stakeholders, as
well as strategic collaborations. These factors are poised to
enhance the overall growth of the radioimmunoassay market from 2024
to 2030.
LAS VEGAS, April 18, 2024 /PRNewswire/ -- DelveInsight's
Radioimmunoassay Market Insights report provides the
current and forecast market analysis, individual leading
radioimmunoassay companies' market shares, challenges,
radioimmunoassay market drivers, barriers, trends, and key market
radioimmunoassay companies in the market.
Key Takeaways from the Radioimmunoassay Market Report
- As per DelveInsight estimates, North
America is anticipated to dominate the global
radioimmunoassay market during the forecast period.
- As per the analysis, the global radioimmunoassay market was
valued at USD 523.98 million
in 2023.
- Notable radioimmunoassay companies such as DIAsource, MP
BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science,
Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher
Corporation, and several others, are currently operating in the
radioimmunoassay market.
To read more about the latest highlights related to the
radioimmunoassay market, get a snapshot of the key highlights
entailed in the Global Radioimmunoassay Market Report
Radioimmunoassay Overview
Radioimmunoassay stands as a groundbreaking technique in the
field of medicine and biology, revolutionizing the way researchers
detect and measure tiny concentrations of biological substances.
Developed in the 1950s by Dr. Rosalyn
Yalow and Dr. Solomon Berson,
this method uses the specific binding of antibodies to antigens to
quantify substances like hormones, enzymes, and drugs. In RIA, a
known radioactive substance is added to a sample containing the
substance of interest. Then, an antibody that recognizes the
substance binds to it, forming a complex. The amount of
radioactivity in the complex is directly proportional to the
concentration of the substance in the sample, allowing for highly
sensitive measurements in the picomolar to nanomolar range. This
remarkable precision has made RIA indispensable in diagnosing
conditions such as thyroid disorders, diabetes, and various
hormonal imbalances.
Furthermore, the versatility of Radioimmunoassay extends beyond
clinical settings, finding applications in research laboratories
worldwide. Scientists rely on RIA to unravel intricate mechanisms
of disease progression, monitor drug levels in patients, and
investigate the role of hormones in physiological processes. Its
ability to detect substances in minute quantities with high
accuracy has propelled advancements in fields ranging from
pharmacology to endocrinology, shaping our understanding of health
and disease at a molecular level. Despite the emergence of newer
technologies, the enduring legacy of Radioimmunoassay continues to
underpin critical medical discoveries, demonstrating the enduring
impact of this pioneering technique in modern science.
Radioimmunoassay Market Insights
In 2023, North America
dominated the radioimmunoassay market, primarily due to several
factors. These include a substantial patient population dealing
with Sexually Transmitted Diseases (STDs), cancer, and other
ailments, a robust environment for product development and
launches, and the strong presence of key market players in the
region. For instance, in 2019, it was estimated by the Centers for
Disease Control and Prevention (CDC) that over 1.1 million people
aged 13 and above were living with HIV in the US, while around 1.75
million new cancer cases were reported.
Additionally, data from the American Thyroid Association in 2019
suggested that roughly 20 million Americans suffer from some form
of thyroid disease, with over 12 percent expected to develop it
during their lifetime. Furthermore, the US government's significant
investment of USD 650 million in
rapid diagnostic testing, as announced by the US Department of
Health and Human Services in 2021, further underlines the favorable
conditions for the radioimmunoassay market's growth in the region.
Consequently, these factors are anticipated to drive the expansion
of the radioimmunoassay market in North
America throughout the forecast period spanning from 2024 to
2030.
To know more about why North
America is leading the market growth in the radioimmunoassay
market, get a snapshot of the Radioimmunoassay Market
Outlook
Radioimmunoassay Market Dynamics
The radioimmunoassay market dynamics have been steadily
evolving, driven by a myriad of factors shaping the healthcare
landscape. One of the key drivers is the growing prevalence of
chronic diseases such as cancer, cardiovascular disorders, and
diabetes. As healthcare providers seek more efficient and
accurate diagnostic tools, radioimmunoassay offers a reliable
method for measuring minute quantities of substances, including
hormones, enzymes, and drugs, in blood samples. This demand for
precise diagnostic solutions has propelled the
radioimmunoassay market forward, as clinicians rely on these tests
for early detection, disease monitoring, and treatment
optimization.
Moreover, technological advancements have played a
pivotal role in the expansion of the radioimmunoassay market.
Automation and miniaturization have enhanced the efficiency of RIA
tests, reducing turnaround times and improving accuracy.
Additionally, the advent of novel biomarkers and
reagents has widened the scope of applications for
radioimmunoassay, further fueling market growth. With an increasing
focus on personalized medicine, there is a rising need for
tailored diagnostic approaches, a demand that the versatility
and sensitivity of radioimmunoassays are uniquely positioned to
fulfill. As such, the radioimmunoassay market continues to
demonstrate resilience and promising prospects amidst the evolving
landscape of healthcare needs and technological innovation.
Get a sneak peek at the radioimmunoassay market dynamics @
Radioimmunoassay Market Dynamics Analysis
Report
Metrics
|
Details
|
Coverage
|
Global
|
Study Period
|
2021–2030
|
Radioimmunoassay Market
CAGR
|
~3%
|
Radioimmunoassay Market
Size by 2030
|
USD 660.31
Million
|
Key Radioimmunoassay
Companies
|
DIAsource, MP
BIOMEDICALS, Merck KGaA, Tecan Trading AG, Svar Life Science,
Institute of Isotopes Co. Ltd., PerkinElmer Inc., Danaher
Corporation, among others
|
Radioimmunoassay Market Assessment
- Radioimmunoassay Market Segmentation
-
- Radioimmunoassay Market Segmentation By Product Type:
Analyzers And Reagents & Kits
- Radioimmunoassay Market Segmentation By Application:
Research And Clinical Diagnostics
- Radioimmunoassay Market Segmentation By End User:
Hospitals, Clinical Diagnostic Laboratories, Pharmaceutical
Industries, and Others
- Radioimmunoassay Market Segmentation By Geography:
North America, Europe, Asia-Pacific, and Rest of World
- Porter's Five Forces Analysis, Product Profiles, Case
Studies, KOL's Views, Analyst's View
Which MedTech key players in the radioimmunoassay market are set
to emerge as the trendsetter explore @ Radioimmunoassay
Companies
Table of Contents
1
|
Report
Introduction
|
2
|
Executive
summary
|
3
|
Regulatory and Patent
Analysis
|
4
|
Key Factors
Analysis
|
5
|
Porter's Five Forces
Analysis
|
6
|
Radioimmunoassay Market
Layout
|
7
|
Global Company Share
Analysis – Key 3-5 Companies
|
8
|
Radioimmunoassay
Market Company and Product
Profiles
|
9
|
Project
Approach
|
10
|
About
DelveInsight
|
Interested in knowing the radioimmunoassay market by 2030? Click
to get a snapshot of the Radioimmunoassay Market
Trends
Related Reports
Cancer Therapy Market
Cancer Therapy Market Insight, Competitive
Landscape, and Market Forecast – 2030 report delivers an
in-depth understanding of market trends, market drivers, market
barriers, and key cancer therapy companies, including
GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche
Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis
AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead
Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian
Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical,
Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt.
Ltd., among others.
Oncology Drugs Market
Oncology Drugs Market Insight, Competitive
Landscape, and Market Forecast – 2030 report delivers an
in-depth understanding of market trends, market drivers, market
barriers, and key oncology drugs companies, including
GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche
Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis
AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead
Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex
Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma
Inc., Genentech, Inc., Sandoz International GmbH, and BeiGene,
among others.
Cancer Biomarkers Market
Cancer Biomarkers Market Insight, Competitive
Landscape, and Market Forecast – 2030 report delivers an
in-depth understanding of market trends, market drivers, market
barriers, and key cancer biomarkers companies, including F.
Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN
N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott
Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent
Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc.,
Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens
Healthineers, Exact Sciences, R&D Systems, Inc., BioVision,
Inc., among others.
Intratumoral Cancer Therapies Market
Intratumoral Cancer Therapies Market Insight,
Epidemiology, and Market Forecast – 2032 report delivers an
in-depth understanding of market trends, market drivers, market
barriers, along with emerging drugs and key intratumoral cancer
therapies companies, including Daiichi Sankyo, Amgen,
Idera Pharmaceuticals, Philogen, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
https://www.delveinsight.com/medical-devices
Logo:
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/global-radioimmunoassay-market-to-grow-at-a-minimal-cagr-of-3-by-2030--delveinsight-302119200.html